ArticleInternational journal of cancer2020
Detection of tumors with fluoromarker-releasing bacteria.
Article in International journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- The gut-tumor connection: the role of microbiota in cancer progression and treatment strategies.Journal of advanced research · 2026Review
- Attenuated Bacteria-Based Tumor Therapy: Clinical Application Risks, Marketing Approval Restrictions, and Coping Strategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Artificially Engineered Synthetic Biomarkers Revolutionizing Early Diagnosis of Diseases.Molecules (Basel, Switzerland) · 2025Review
- Designing live bacterial therapeutics for cancer.Advanced drug delivery reviews · 2025Review
- AND-gated protease-activated nanosensors for programmable detection of anti-tumour immunity.Nature nanotechnology · 2025Article
- Gut microbiota and its therapeutic implications in tumor microenvironment interactions.Frontiers in microbiology · 2024Review
- Engineering bacteria as interactive cancer therapies.Science (New York, N.Y.) · 2022Review
- Bacteria-Based Synergistic Therapy in the Backdrop of Synthetic Biology.Frontiers in oncology · 2022Review
- Synthetic biomarkers: a twenty-first century path to early cancer detection.Nature reviews. Cancer · 2021Review
- Perspectives on OncolyticFrontiers in immunology · 2021Review
- Homologous Quorum Sensing Regulatory Circuit: A Dual-Input Genetic Controller for Modulating Quorum Sensing-Mediated Protein Expression inACS synthetic biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Combining the specificity of tumor-targeting bacteria with the sensitivity of biomarker detection would create a screening method able to detect small tumors and metastases. To create this system, we genetically modified an attenuated strain of Salmonella enterica to release a recombinant fluorescent biomarker (or fluoromarker). Salmonella expressing ZsGreen were intravenously administered to tumor-bearing mice and fluoromarker production was induced after 48 hr. The quantities and locations of bacteria and ZsGreen were measured in tumors, livers and spleens by immunofluorescence, and the plasma concentration of ZsGreen was measured using single-layer ELISA. In the plasma, the ZsGreen concentration was in the range of 0.5-1.5 ng/ml and was dependent on tumor mass (with a proportion of 0.81 ± 0.32 ng·ml
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.